Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia
Terminated · Phase 2 · NCT06067425
Conditions: Osteochondrodysplasia
At a glance
- Research payments reported, 2025
- $38,880
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 16
About the trial
- Sponsor
- Sanofi
- Tested
- SAR442501 (drug)
- Dates
- Started 2023-10-10; completion 2025-02-12
- Results posted
- Yes
This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.
From ClinicalTrials.gov, last updated 2026-06-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $38,880 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.